Search Result

Results for "

PDK

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PDK-1 (26) Akt (4) Antibiotic (1) Apoptosis (8) Autophagy (4) Bacterial (1) Cannabinoid Receptor (1) Caspase (1) CDK (1) EGFR (1) HIF/HIF Prolyl-Hydroxylase (2) HPV (1) HSP (2) IKK (2) Integrin (1) JNK (1) Mitochondrial Metabolism (1) Monoamine Oxidase (1) mTOR (1) Parasite (1) PDHK (13) Prostaglandin Receptor (1) PROTACs (1) Pyruvate Kinase (2) Ser/Thr Protease (1) Small Interfering RNA (siRNA) (6)
By Research Areas:	Cancer (37) Cardiovascular Disease (2) Infection (2) Inflammation/Immunology (6) Metabolic Disease (5) Neurological Disease (2)
Oligonucleotides:	Pre-designed siRNA Sets (6) siRNAs (6)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

Targets Recommended: PDK-1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-117809

PDK1-IN-2	PDK-1	Cancer
PDK1-IN-2 is a small molecule inhibitor of 3-phosphoinositol-dependent protein kinase-1 (PDK1). PDK1-IN-2 inhibits the binding of *PDK1* to its substrate by competitively binding to the PIF pocket of *PDK1, thereby inhibiting the kinase activity and downstream signaling of PDK1. PDK*1-IN-2 can be used for cell survival and proliferation in cancer .

HY-157299

PDK-IN-3	PDHK	Cancer
PDK-IN-3 (compound 1) is a potent pan inhibitor of *PDK* with IC₅₀s of 109.3, 135.8, 458.7 nM and 8.67 μM against PDK 1-4, respectively. PDK-IN-3 also induces proliferation and apoptosis in A549 cells .

HY-149814

PDK-IN-1	PDHK HSP	Cancer
PDK-IN-1 (compound 7o) is a pyruvate dehydrogenase kinase (PDK) inhibitor. PDK-IN-1 shows IC₅₀ values of 0.03 and 0.1 μM for *PDK1* and HSP90, respectively. PDK-IN-1 targets PDH/PDK axis thus reducing efficiently the tumor mass .

HY-135954A

PDK4-IN-1 hydrochloride 2 Publications Verification	PDHK Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
PDK4-IN-1 hydrochloride is an anthraquinone derivative and a potent and orally active pyruvate dehydrogenase kinase 4 (PDK4) inhibitor with an IC₅₀ value of 84 nM. PDK4-IN-1 hydrochloride potently represses cellular transformation and cellular proliferation and induces apoptosis. PDK4-IN-1 hydrochloride has antidiabetic, anticancer and anti-allergic activity .

HY-135954

PDK4-IN-1 2 Publications Verification	PDHK Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
PDK4-IN-1 is an anthraquinone derivative and a potent and orally active pyruvate dehydrogenase kinase 4 (PDK4) inhibitor with an IC₅₀ value of 84 nM. PDK4-IN-1 potently represses cellular transformation and cellular proliferation and induces apoptosis. PDK4-IN-1 has antidiabetic, anticancer and anti-allergic activity .

HY-W070306

PDK1-IN-1	PDK-1	Neurological Disease Cancer
PDK1-IN-1 (Compound 2-11) is a *PDK1* inhibitor, and can be used for research of myeloproliferative disorders or cancer .

HY-114645

PDK1-IN-RS2	PDK-1	Cancer
PDK1-IN-RS2 is a mimic of peptide docking motif (PIFtide) and is a substrate-selective *PDK1* inhibitor with a K_d of 9 μM. PDK1-IN-RS2 suppresses the activation of the downstream kinases S6K1 by *PDK1* .

HY-156109

PDK-IN-2	PDHK Mitochondrial Metabolism	Cancer
PDK-IN-2 (Compound 1F) is a *PDK* inhibitor (IC₅₀: 68 nM). PDK-IN-2 inhibits the cellular expression of PDK1 and PDK4. PDK-IN-2 enhances mitochondrial bioenergetics, attenuates glycolytic phenotypes, and induces cell apoptosis in the mitochondrial pathway. PDK-IN-2 inhibits tumor growth in 4T1 syngeneic mice model .

HY-157538

PDK4-IN-2	PDHK	Cardiovascular Disease
PDK4-IN-2 (compound 8) is a pyruvate dehydrogenase kinase 4 (PDK4) inhibitor with an IC₅₀ of 46 µM. PDK4-IN-2 improves ejection fraction of failing hearts by regulating bioenergetics via activation of the tricarboxylic acid cycle .

HY-124288

PDK1/AurA-IN-1	Others	Others
PDK1/AurA-IN-1 is an active compound.

HY-14440

MP7 1 Publications Verification PDK1 inhibitor	PDK-1	Cancer
MP7 (PDK1 inhibitor) is a phosphoinositide-dependent kinase-1 (PDK1) inhibitor.

HY-129426

PDK1/Akt/Flt dual pathway inhibitor	Akt	Cancer
PDK1/Akt/Flt dual pathway inhibitor is one of a component of KP372-1 (HY-15673 ), and inhibits PDK1/Akt/Flt dual pathway .

HY-W837864

PDK1 allosteric modulator 1	Others	Others
PDK1 allosteric modulator 1 is a molecule targeting PDK1 with a binding affinity of 8 μM. PDK1 allosteric modulator 1 is able to bind to the PIF pocket of PDK1, potentially affecting the biological activity of this kinase .

HY-10547

OSU-03012 4 Publications Verification AR-12; PDK1 inhibitor AR-12	PDK-1 Autophagy	Cancer
OSU-03012 (AR-12; PDK1 inhibitor AR-12) is a blood-brain permeable *PDK-1* inhibitor with an IC₅₀ of 5 μM .

HY-RS10273

PDK1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PDK1 Human Pre-designed siRNA Set A contains three designed siRNAs for PDK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PDK1 Human Pre-designed siRNA Set A PDK1 Human Pre-designed siRNA Set A

HY-RS10274

Pdk1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Pdk1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pdk1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pdk1 Mouse Pre-designed siRNA Set A Pdk1 Mouse Pre-designed siRNA Set A

HY-RS10275

Pdk1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Pdk1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Pdk1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pdk1 Rat Pre-designed siRNA Set A Pdk1 Rat Pre-designed siRNA Set A

HY-RS10276

PDK2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PDK2 Human Pre-designed siRNA Set A contains three designed siRNAs for PDK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PDK2 Human Pre-designed siRNA Set A PDK2 Human Pre-designed siRNA Set A

HY-RS10277

PDK3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PDK3 Human Pre-designed siRNA Set A contains three designed siRNAs for PDK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PDK3 Human Pre-designed siRNA Set A PDK3 Human Pre-designed siRNA Set A

HY-RS10278

PDK4 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PDK4 Human Pre-designed siRNA Set A contains three designed siRNAs for PDK4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PDK4 Human Pre-designed siRNA Set A PDK4 Human Pre-designed siRNA Set A

HY-P5450

PDKtide	PDK-1	Others
PDKtide is a biological active peptide. (This peptide is a substrate for PDK1 (Phosphatidylinositide-Dependent Kinase 1).)

HY-149275

*PKM2/PDK1-IN-1*	Pyruvate Kinase PDK-1 Akt EGFR Apoptosis	Cancer
PKM2/PDK1-IN-1, one of shikonin thioether derivatives, is a dual inhibitor of *PKM2/PDK1*. PKM2/PDK1-IN-1 inhibits the proliferation of NSCLC cells, and induces apoptosis. PKM2/PDK1-IN-1 induces intercellular ROS production, and regulates the apoptotic proteins, to involves in mitochondrial and death receptor pathway .

HY-146977

LDHA/PDKs-IN-1	PDK-1	Cancer
LDHA/PDKs-IN-1 (compound 20e) is a potent and dual inhibitor of PDKs and LDHA with IC₅₀s of 0.8 and 0.15 μM, respectively. LDHA/PDKs-IN-1 reduces A549 cell proliferation with an EC₅₀ of 13.2 μM and decreases the lactate formation, and increases oxygen consumption. LDHA/PDKs-IN-1 has the potential for the research of cancer diseases .

HY-146978

LDHA/PDKs-IN-2	PDK-1	Cancer
LDHA/PDKs-IN-2 (compound 20k) is a potent and dual inhibitor of PDKs and LDHA with IC₅₀s of 1.6 and 0.7 μM, respectively. LDHA/PDKs-IN-2 reduces A549 cell proliferation with an EC₅₀ of 15.7 μM and decreases the lactate formation, and increases oxygen consumption. LDHA/PDKs-IN-2 has the potential for the research of cancer diseases .

HY-12492

VER-246608 2 Publications Verification	PDHK	Cancer
VER-246608 is a potent and ATP-competitive inhibitor of pyruvate dehydrogenase kinase (PDK) with IC₅₀s of 35 nM, 40 nM, 84 nM, and 91 nM for *PDK-1, PDK-3, PDK-2, and PDK-4*, respectively.

HY-121744

PS10 2 Publications Verification	PDHK	Inflammation/Immunology
PS10 is a novel, potent and ATP-competitive pan-PDK* inhibitor,* inhibits all PDK isoforms with IC₅₀ of 0.8 μM, 0.76 μM, 2.1 μM and 21.3 μM for PDK2, PDK4, PDK1, and PDK3, respectively. PS10 shows high affinity for PDK2 (K_d= 239 nM) than for Hsp90 (K_d= 47 μM) . PS10 improves glucose tolerance, stimulates myocardial carbohydrate oxidation in diet-induced obesity. PS10 has the potential for the investigation of diabetic cardiomyopathy ^[2].PDK: pyruvate dehydrogenase kinase

HY-W005629

Leelamine	Cannabinoid Receptor PDK-1	Metabolic Disease Cancer
Leelamine is an orally active pyruvate dehydrogenase kinase (PDK) inhibitor with an IC₅₀ value of 9.5 μM, showing a blood glucose lowering effect in the diabetic mouse. Leelamine is also a weak agonist of cannabinoid receptors CB1 and CB2. Leelamine decreases mitotic activity, prostate-specific antigen expression and induces Apoptosis to cell death in cancer cells .

HY-19564

JX06 1 Publications Verification	PDHK Apoptosis	Cancer
JX06 is a potent, selective and covalent inhibitor of *PDK. JX06 inhibits PDK1, PDK2* and *PDK3* with IC₅₀s of 49 nM, 101 nM, and 313 nM, respectively. JX06 inhibits PDK1 activity via covalently binding to a cysteine residue in an irreversible manner. JX06 shows significant antitumor activity .

HY-124060

PS423	PDK-1	Cancer
PS423 is a prodrug of PS210, acting as a substrate-selective inhibitor of *PDK1, inhibiting the phosphorylation and activation of S6K. PS210 is a potent and selective PDK1 activator targeting the PIF binding pocket of PDK*1 .

HY-121629

PS210	PDK-1	Cancer
PS210 is a potent and selective *PDK1* activator with a K_d of 3 μM and targets the PIF-binding pocket of *PDK1. PS210 is inactive against other protein kinases, including PDK1* downstream signaling components such as S6K, PKB/Akt or GSK3. In cells, the prodrug of PS210 (PS423) acts as a substrate-selective inhibitor of *PDK1*, inhibiting the phosphorylation and activation of S6K .

HY-11005

BX-912 4 Publications Verification	PDK-1 Apoptosis	Cancer
BX-912 is a direct, selective, and ATP-competitive *PDK1* inhibitor (IC₅₀=26 nM). BX-912 blocks PDK1/Akt signaling in tumor cells and inhibits the anchorage-dependent growth of a variety of tumor cell lines in culture or induces apoptosis .

HY-13842

BX517 1 Publications Verification	PDK-1	Cancer
BX517 is a potent and selective inhibitor of *PDK1* with IC₅₀ of 6 nM.

HY-15967

PS48 5 Publications Verification	PDK-1	Cancer
PS48 is an activator of *PDK1* with an AC₅₀ of 8 μM.

HY-N6769

Radicicol 3 Publications Verification Monorden	HSP Bacterial Antibiotic Parasite	Infection
Radicicol is an inhibitor of Hsp90 with an IC₅₀ value < 1 μM, and leads to proteasomal degradation . Radicicol exhibits inhibition on *PDK* with IC₅₀s of 230 μM (PDK1) and 400 μM (PDK3). Radicicol is an antifungal and antimalarial antibiotic, impairs mitochondrial replication by targeting P. falciparum topoisomerase VIB . Radicicol is also an inhibitor of fat mass and obesity-associated protein (FTO), with an IC₅₀ value of 16.04 μM .

HY-14981

GSK2334470 5+ Cited Publications	PDK-1	Cancer
GSK2334470 is a highly specific and potent inhibitor of *PDK1* with an IC₅₀ of 10 nM.

HY-117885

PF-5177624	PDK-1	Cancer
PF-5177624 is a specific and potent inhibitor of PDK1, a key enzyme in the PI3K/AKT signaling pathway that is frequently dysregulated in breast cancer. PDK1 phosphorylates AKT at T308 and other substrates, activating downstream signaling pathways that are important for tumor progression. PF-5177624 blocks IGF-1-stimulated PDK1 activity and downstream AKT and p70S6K phosphorylation, reducing cell proliferation and transformation in breast cancer cells .

HY-N0047

Polyphyllin I 1 Publications Verification	JNK mTOR Akt PDK-1 Autophagy Apoptosis	Cancer
Polyphyllin I is a bioactive constituent extracted from Paris polyphylla, has strong anti-tumor activity. Polyphyllin I is an activator of the JNK signaling pathway and is an inhibitor of *PDK1/Akt/mTOR* signaling. Polyphyllin I induces autophagy, G2/M phase arrest and apoptosis .

HY-13856

(R)-PS210	PDK-1	Cancer
(R)-PS210, the R enantiomer of PS210 (compound 4h-eutomer), is a substrate-selective allosteric activator of *PDK1* with an AC₅₀ value of 1.8 μM. (R)-PS210 targets to the PIF-binding pocket of PDK1. PIF: The protein kinase C-related kinase 2 (PRK2)-interacting fragment .

HY-W998345

SMART1	PROTACs PDK-1 Akt	Cancer
SMART1 is a highly specific and CRBN-dependent PROTAC that can effectively degrade Smurf1. SMART1 can block the *PDK1-Akt* signaling pathway in KRAS mutant colorectal cancer. SMART1 can inhibit tumor growth in KRAS mutant colorectal cancer (CRC) xenograft models.(Blue: CRBN ligand; Black: linker; Pink: Smurf1 ligand (Smurf1-L)) .

HY-N0645

Dicoumarol 5+ Cited Publications Dicumarol	PDHK	Cancer
Dicoumarol is an inhibitor of both NAD(P)H:quinone oxidoreductase 1 (NQO1) and *PDK1* with IC₅₀s of 0.37 and 19.42 μM, respectively.

HY-13851

PS47	PDK-1	Others
PS47 is an inactive E-isomer of PS48. PS48 is an activator of PDK1. PS47 can be used as a negative control for PS48 .

HY-128578

KPLH1130	PDHK	Metabolic Disease Inflammation/Immunology
KPLH1130 is a specific pyruvate dehydrogenase kinase (PDK) inhibitor, blocks macrophage polarization and attenuates proinflammatory responses. KPLH1130 improves glucose tolerance in HFD-fed mice .

HY-114702

M77976 1 Publications Verification	PDHK	Metabolic Disease
M77976 is a specific ATP-competitive inhibitor of PDK4 (pyruvate dehydrogenase kinase isoforms 4), with an IC₅₀ of 648 μM. M77976 is potential for the research of obesity and diabetes .

HY-124379

TPCK 1 Publications Verification L-1-Tosylamido-2-phenylethyl chloromethyl ketone; L-TPCK	Ser/Thr Protease HPV Apoptosis PDK-1	Infection Neurological Disease Inflammation/Immunology Cancer
TPCK (L-1-Tosylamido-2-phenylethyl chloromethyl ketone; L-TPCK) is an effective serine protease inhibitor and also a blocker of the *PDK1/Akt* pathway. TPCK can modify the E7 protein in actively keratinocyte cells. TPCK can induce cellular apoptosis, suppress tumor growth, reduce hypoxic-ischemic brain injury in rat pups, and affect vascular permeability in inflamed rats .

HY-10515

BX-320	PDK-1	Cancer
BX-320 is a selective, ATP-competitive, orally acitive, and direct *PDK1* inhibitor with an IC₅₀ of 30 nM in a direct kinase assay format. BX-320 also induces apoptosis. Anticancer effect .

HY-116257

GSK-7227	Others	Others
GSK-7227 (compound 32) is a PPARδ partial agonist with the activity of regulating the expression of related genes. GSK-7227 has partial agonist effects on PPARδ target genes CPT1a and PDK4 in skeletal muscle cells.

HY-135773

CRTh2 antagonist 3	Prostaglandin Receptor PDK-1	Cardiovascular Disease Inflammation/Immunology
CRTh2 antagonist 3 is a potent chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2) antagonist . CRTh2 antagonist 3 enhances the activity of PDK1 toward a short peptide substrate, with an EC₅₀ of 2 μM and a K_d of 8.4 μM. CRTh2 antagonist 3 has the potential for cardiovascular inflammation .

HY-151465

HIF-1α-IN-4	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-1α-IN-4 is a HIF-1α inhibitor with an IC₅₀ value of 24 nM (in HEK293T cell). HIF-1α-IN-4 downregulates VEGF and PDK1 mRNA expressions under hypoxia. HIF-1α-IN-4 can be used in the research of cancer .

HY-10514

BX795 Maximum Cited Publications 26 Publications Verification	PDK-1 IKK Autophagy	Cancer
BX795 is a potent and selective inhibitor of *PDK1, with an IC₅₀* of 6 nM. BX795 is also a potent and relatively specific inhibitor of TBK1 and IKKε, with an IC₅₀ of 6 and 41 nM, respectively. BX795 blocks phosphorylation of S6K1, Akt, PKCδ, and GSK3β, and has lower selectivity over PKA, PKC, c-Kit, GSK3β etc. BX795 modulates autophagy .

HY-18676B

ILK-IN-2 OSU-T315 analog	Integrin Autophagy Apoptosis Caspase PDHK	Cancer
ILK-IN-2 (OSU-T315 analog) is an oral *PDK2* inhibitor and also an ILK inhibitor, with an IC₅₀ of 0.6 μM. ILK-IN-2 induces cell autophagy and apoptosis, showing anti-tumor activity. ILK-IN-2 directly abolishes AKT activation by preventing AKT from translocating to lipid rafts, triggering Caspase-dependent apoptosis in chronic lymphocytic leukemia (CLL) and extending the lifespan in TCL1 mouse models .

Cat. No.	Product Name

HY-L015

PI3K/Akt/mTOR Compound Library

616 compounds

The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials.

MCE owns a unique collection of 616 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-P5450

PDKtide	PDK-1	Others
PDKtide is a biological active peptide. (This peptide is a substrate for PDK1 (Phosphatidylinositide-Dependent Kinase 1).)

Species:	Human (3) Mouse (2)
Tag:	His (4) GST (3)
Source:	Sf9 insect cells (3) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P73718

	PDK1 Protein, Human (sf9, His) Pyruvate dehydrogenase kinase isoform 1; PDK1; PDHK1	Human	Sf9 insect cells
	PDK1 protein is a key kinase that controls glucose and fatty acid metabolism by phosphorylating pyruvate dehydrogenase subunits PDHA1 and PDHA2. This molecular switch inhibits pyruvate dehydrogenase, fine-tunes metabolite flux and downregulates aerobic respiration. PDK1 Protein, Human (sf9, His) is the recombinant human-derived PDK1 protein, expressed by Sf9 insect cells , with N-His labeled tag. The total length of PDK1 Protein, Human (sf9, His) is 408 a.a., with molecular weight of ~45 kDa.

HY-P701737

	PDK4 Protein, Human (GST) PDK4; [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4; mitochondrial; Pyruvate dehydrogenase kinase isoform 4	Human	E. coli
	PDK4 Protein phosphorylates PDHA1 and PDHA2, inhibiting pyruvate dehydrogenase activity. This reduces glucose utilization, enhances fat metabolism, and helps maintain blood glucose levels during fasting. PDK4 also regulates fatty acid oxidation and biosynthesis, generates reactive oxygen species, protects epithelial cells, and regulates cell proliferation through metabolic regulation. PDK4 Protein, Human (GST) is the recombinant human-derived PDK4 protein, expressed by E. coli , with N-GST labeled tag. The total length of PDK4 Protein, Human (GST) is 411 a.a., .

HY-P71614

	PDK3 Protein, Mouse (His) PDK3; Pyruvate dehydrogenase kinase isoform 3	Mouse	E. coli
	PDK3 is a metabolic regulator that inhibits pyruvate dehydrogenase through PDHA1 phosphorylation to fine-tune glucose metabolism and affect aerobic respiration. Phosphorylation of PDHA2 adds another layer of control. PDK3 Protein, Mouse (His) is the recombinant mouse-derived PDK3 protein, expressed by E. coli , with N-His labeled tag.

HY-P74639

	PDK4 Protein, Mouse (sf9, His-GST) Pyruvate dehydrogenase kinase isoform 4; PDK4; PDHK4	Mouse	Sf9 insect cells
	PDK4 protein is a key kinase that regulates glucose and fatty acid metabolism by phosphorylating pyruvate dehydrogenase subunits PDHA1 and PDHA2.This inhibits pyruvate dehydrogenase activity, modulates metabolite flux and inhibits aerobic respiration.PDK4 Protein, Mouse (sf9, His-GST) is the recombinant mouse-derived PDK4 protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

HY-P703578

	PDK3 Protein, Human (Inactive, Sf9, His, GST) PDHK3	Human	Sf9 insect cells
	PDK3 Protein, Human (Inactive, Sf9, His, GST) is the recombinant human-derived PDK3, expressed by Sf9 insect cells , with His, GST labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80272

	PDK1 Antibody	WB, IHC-P, IP, FC	Human, Mouse, Rat
	PDK1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 49 kDa, targeting to PDK1. It can be used for WB,IHC-P,IP,FC assays with tag free, in the background of Human, Mouse, Rat.

HY-P81650

	PDK2 Antibody (YA1395) PDK2; PDHK2; [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 2; mitochondrial; Pyruvate dehydrogenase kinase isoform 2	WB, IHC-P, ICC/IF, IP, FC	Human, Mouse, Rat
	PDK2 Antibody (YA1395) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1395), targeting PDK2, with a predicted molecular weight of 46 kDa (observed band size: 46 kDa). PDK2 Antibody (YA1395) can be used for WB, IHC-P, ICC/IF, IP, FC experiment in human, mouse, rat background.

HY-P81824

	PDPK1 Antibody (YA1569) PDPK1; PDK1; 3-phosphoinositide-dependent protein kinase 1; hPDK1	WB	Human, Mouse, Rat
	PDPK1 Antibody (YA1569) is a biotin-conjugated non-conjugated IgG antibody, targeting PDPK1, with a predicted molecular weight of 63 kDa (observed band size: 63 kDa). PDPK1 Antibody (YA1569) can be used for WB experiment in human, mouse, rat background.